Sol-Gel(SLGL) - 2025 Q4 - Annual Report

Financial Performance - The company incurred a net loss of $27.2 million in 2023, $10.6 million in 2024, and $6.1 million in 2025, with an accumulated deficit of $237 million as of December 31, 2025[38]. - The company anticipates ongoing losses as it invests in research and development and seeks regulatory approvals for its product candidates[38]. - The company expects continued significant expenses and operating losses over the next several years as it conducts advanced-stage clinical studies for SGT-610 and develops SGT-210[43]. - The company may need to raise substantial additional funding to pursue its business objectives, which could lead to dilution of shareholder value[43]. Product Development and Regulatory Approval - The company has not yet obtained regulatory approval for its product candidates in the United States or any other country, which poses a risk to its business[31]. - The company may face increased costs and delays in the marketing approval process if the FDA requires additional studies or data for its product candidates[49]. - The company expects to utilize the FDA's Section 505(b)(2) pathway for some product candidates, but if unavailable, development could take significantly longer and cost more[79]. - The company has filed two NDAs under Section 505(b)(2) of the FDCA, with Twyneo receiving FDA marketing approval in July 2021 and Epsolay in April 2022[189]. - The company may be required to perform additional clinical trials to support changes from branded reference drugs, potentially delaying regulatory approvals[192]. Market Competition and Commercialization - The company faces intense competition in the dermatology market, which may hinder its ability to achieve commercial success[31]. - The company’s future success is highly dependent on the market perception of its products and their safety and quality[31]. - The company faces significant competition for its product candidates, including SGT-610, Twyneo, and Epsolay, from established companies with greater resources and market experience[126][129]. - Sales of SGT-610, Twyneo, and Epsolay will depend heavily on third-party payor coverage and reimbursement levels, which are critical for profitability[135]. Clinical Trials and Patient Enrollment - The company may face challenges in enrolling patients for clinical trials, which could delay the development of its product candidates[31]. - The company faces intense competition for patient enrollment in clinical trials, which could delay or prevent the trials from proceeding[68]. - The company is dependent on ongoing clinical trials, and any delays could significantly harm its ability to generate product revenues[66]. - The company may experience delays in clinical trials due to various factors, including patient recruitment challenges and regulatory compliance issues[63]. Intellectual Property and Legal Risks - The company’s success is contingent on its ability to protect its intellectual property, which involves complex legal challenges[173]. - The company may face patent infringement lawsuits that could delay or prevent the review or approval of its product candidates[189]. - The company has granted licenses to third parties for its intellectual property, which may lead to increased competition and reduced market share[179]. - The company may incur substantial costs and management resource diversion due to legal proceedings related to intellectual property rights[183]. Regulatory Environment and Compliance - The company must comply with extensive regulatory requirements, including manufacturing and labeling, which could affect the commercial viability of its products[93]. - The enforcement of healthcare laws is uncertain and may change rapidly, complicating compliance efforts and diverting resources[141]. - The company faces risks related to compliance with healthcare regulatory laws, which could lead to significant penalties and operational impacts[139]. - Regulatory approval processes are lengthy and unpredictable, with the potential for changes in approval policies that could affect the company's product candidates[69]. Operational Challenges - The company relies on third-party partners for the commercialization of its products, which may affect its ability to achieve significant market penetration[31]. - The company is dependent on contract manufacturers for compliance with cGMP requirements, and any failure could jeopardize regulatory approvals[162]. - Manufacturing difficulties could significantly impact the ability to provide product candidates to patients and delay commercialization efforts[171]. - The company relies on third-party manufacturers for the production of product candidates and approved products, increasing risks related to supply and compliance[161]. External Factors and Risks - The company faces significant risks due to political, economic, and military conditions in Israel, which could adversely affect its operations and financial condition[196]. - Recent hostilities, including attacks from Hamas and Hezbollah, have escalated tensions in the region, potentially impacting the company's ability to conduct business[197]. - Exchange rate fluctuations between the U.S. dollar and the New Israeli Shekel may negatively impact future revenues, as a substantial portion of revenues is expected to be generated in foreign currencies[201]. - The company may face claims for remuneration or royalties for assigned service invention rights by employees, which could lead to litigation and adversely affect its business[211].